Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
30 hedge funds and large institutions have $2.14M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0% more funds holding
Funds holding: 30 → 30 (0)
39% less capital invested
Capital invested by funds: $3.5M → $2.14M (-$1.36M)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$17.1K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$11.6K |
| 3 |
Jane Street
New York
|
+$5.57K |
| 4 |
AI
Atom Investors
Austin,
Texas
|
+$4.51K |
| 5 |
VF
Virtu Financial
New York
|
+$4.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.4K |
| 2 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$21.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$16K |
| 4 |
Renaissance Technologies
New York
|
-$13.8K |
| 5 |
Two Sigma Advisers
New York
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| $83 | – | – | – |
|
|
27
Two Sigma Advisers
New York
| – | -$13K | -1,233 | Closed |
|
|
MAM
28
Meeder Asset Management
Dublin,
Ohio
| – | -$11.7K | -976 | -98% |
|
29
D.E. Shaw & Co
New York
| – | -$6K | -532 | Closed |
|
30
JP Morgan Chase
New York
| – | +$12 | +1 | +100% |
|
31
Simplex Trading
Chicago,
Illinois
| – | +$120 | +10 | +500% |
|
ELOX Hedge Fund Activity: Q3 2022 in Review
30 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q3 2022, worth a combined $2.14M — down 39% from $3.5M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ELOX positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 10 trimmed.
The largest buyer was Silverarc Capital Management, adding an estimated $17.1K. The largest seller was Vanguard Group, cutting an estimated $35.4K.
- 30 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $2.14M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q3 2022, down 39% quarter-over-quarter.
- 3 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of +1 holder.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Silverarc Capital Management, an estimated $17.1K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $35.4K sold.
Based on aggregated 13F filings for Q3 2022.